Cargando…

Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-κB/GLUT1 axis

Non-small-cell lung cancer (NSCLC) is an aggressive malignancy and long-term survival remains unsatisfactory for patients with metastatic and recurrent disease. Repurposing the anti-malarial drug dihydroartemisinin (DHA) has been proved to possess potent antitumor effect on various cancers. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Jie, Geng, Guojun, Yu, Xiuyi, Liu, Hongming, Gao, Jing, An, Hanxiang, Cai, Chengfu, Li, Ning, Shen, Dongyan, Wu, Xiaoqiang, Zheng, Lisheng, Mi, Yanjun, Yang, Shuyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349987/ https://www.ncbi.nlm.nih.gov/pubmed/27895313 http://dx.doi.org/10.18632/oncotarget.13536

Ejemplares similares

Dihydroartemisinin inhibits catabolism in rat chondrocytes by activating autophagy via inhibition of the NF-κB pathway
por: Jiang, Li-Bo, et al.
Publicado: (2016)

Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling
por: Hodel, Eva Maria, et al.
Publicado: (2014)

Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to anti-malarial agent dihydroartemisinin
por: Elf, Shannon, et al.
Publicado: (2016)

Anti-malarial drug dihydroartemisinin downregulates the expression levels of CDK1 and CCNB1 in liver cancer
por: Hao, Liyuan, et al.
Publicado: (2021)

Repurposing Dihydroartemisinin to Combat Oral Squamous Cell Carcinoma, Associated with Mitochondrial Dysfunction and Oxidative Stress
por: Shi, Shanwei, et al.
Publicado: (2023)

Dihydroartemisinin Inhibits the Proliferation of Leukemia Cells K562 by Suppressing PKM2 and GLUT1 Mediated Aerobic Glycolysis
por: Gao, Peng, et al.
Publicado: (2020)

NF-κB Signaling and Inflammation—Drug Repurposing to Treat Inflammatory Disorders?
por: Roberti, Annabell, et al.
Publicado: (2022)

Oncoprotein LAMTOR5 Activates GLUT1 Via Upregulating NF-κB in Liver Cancer
por: Zhou, Jing, et al.
Publicado: (2019)

Repurposing the anti-malarial drug, quinacrine: new anti-colitis properties
por: Chumanevich, Alexander A., et al.
Publicado: (2016)

Dihydroartemisinin attenuates autoimmune thyroiditis by inhibiting the CXCR3/PI3K/AKT/NF-κB signaling pathway
por: Liu, Huijuan, et al.
Publicado: (2017)

Dihydroartemisinin Attenuated Intervertebral Disc Degeneration via Inhibiting PI3K/AKT and NF-κB Signaling Pathways
por: Liao, Zhiheng, et al.
Publicado: (2022)

Dihydroartemisinin attenuates lipopolysaccharide-induced acute lung injury in mice by suppressing NF-κB signaling in an Nrf2-dependent manner
por: Huang, Xiao-Ting, et al.
Publicado: (2019)

Drug repurposing applied: Activity of the anti-malarial mefloquine against Echinococcus multilocularis
por: Lundström-Stadelmann, Britta, et al.
Publicado: (2020)

Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy
por: Lemke, Dieter, et al.
Publicado: (2016)

Resistance to Dihydroartemisinin
por: Cojean, Sandrine, et al.
Publicado: (2006)

Resistance to Dihydroartemisinin
por: Legrand, Eric, et al.
Publicado: (2007)

Mechanisms of Dihydroartemisinin and Dihydroartemisinin/Holotransferrin Cytotoxicity in T-Cell Lymphoma Cells
por: Wang, Qiuyan, et al.
Publicado: (2015)

Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF-κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis
por: Ding, Dong, et al.
Publicado: (2022)

Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study
por: Ewing, Victoria L, et al.
Publicado: (2015)

Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018
por: Gansané, Adama, et al.
Publicado: (2021)

Dihydroartemisinin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cell by Upregulating Tumor Necrosis Factor via JNK/NF-κB Pathways
por: Wu, Long, et al.
Publicado: (2019)

Retinol dehydrogenase-10 promotes development and progression of human glioma via the TWEAK-NF-κB axis
por: Guan, Feng, et al.
Publicado: (2017)

Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin–piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia
por: Rahmasari, Farindira Vesti, et al.
Publicado: (2023)

ATRT-05. REPURPOSED ANTI-MALARIAL QUINACRINE ACTIVATES P53 AND INHIBITS ATRT TUMORIGENICITY
por: Kaur, Harpreet, et al.
Publicado: (2021)

Computed tomography-guided preoperative semi-rigid hook-wire localization of small pulmonary nodules: 74 cases report
por: Zhao, Guang, et al.
Publicado: (2019)

LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs
por: Xia, Rongmu, et al.
Publicado: (2021)

Dihydroartemisinin Protects against Dextran Sulfate Sodium-Induced Colitis in Mice through Inhibiting the PI3K/AKT and NF-κB Signaling Pathways
por: Li, Ning, et al.
Publicado: (2019)

Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancer via the NF-κB/MMP-2 signal pathway
por: Tao, Jin, et al.
Publicado: (2018)

Dihydroartemisinin ameliorates innate inflammatory response induced by Streptococcussuis-derived muramidase-released protein via inactivation of TLR4-dependent NF-κB signaling
por: Ji, Yun, et al.
Publicado: (2023)

Enantiomerically pure amino-alcohol quinolines: in vitro anti-malarial activity in combination with dihydroartemisinin, cytotoxicity and in vivo efficacy in a Plasmodium berghei mouse model
por: Mullié, Catherine, et al.
Publicado: (2014)

GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle
por: Aerni-Flessner, Lauren, et al.
Publicado: (2012)

Rocaglamide-A Potentiates Osteoblast Differentiation by Inhibiting NF-κB Signaling
por: Li, Aiguo, et al.
Publicado: (2015)

TUG1/MAZ/FTH1 Axis Attenuates the Antiglioma Effect of Dihydroartemisinin by Inhibiting Ferroptosis
por: Gong, Hailong, et al.
Publicado: (2022)

Dietary dihydroartemisinin supplementation alleviates intestinal inflammatory injury through TLR4/NOD/NF-κB signaling pathway in weaned piglets with intrauterine growth retardation
por: Niu, Yu, et al.
Publicado: (2021)

Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells
por: Barron, Carly, et al.
Publicado: (2012)

Geniposide promotes autophagy to inhibit insulin resistance in HepG2 cells via P62/NF-κB/GLUT-4
por: Jiang, Hongwei, et al.
Publicado: (2017)

The pharmaceutical death-ride of dihydroartemisinin
por: Jansen, Frans Herwig
Publicado: (2010)

Pilot study: bioequivalence of dihydroartemisinin in dihydroartemisinin-piperaquine tablet generic formulation in healthy Indonesian volunteers
por: Isnawati, Ani, et al.
Publicado: (2023)

AMPK-NF-κB Axis in the Photoreceptor Disorder during Retinal Inflammation
por: Kamoshita, Mamoru, et al.
Publicado: (2014)

Oleanolic Acid Attenuates Insulin Resistance via NF-κB to Regulate the IRS1-GLUT4 Pathway in HepG2 Cells
por: Li, Ming, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t72e9f25js1dt7upmogjnhleng